Inhaled Liposomal Ciprofloxacin Nanoparticles Control the Release of Antibiotic at the Bronchial Epithelia

Virginia Commonwealth University
Publication Type:
Conference Proceeding
Respiratory Drug Delivery Proceedings Vol 3, 2012, pp. 527 - 530
Issue Date:
Full metadata record
The cycle of respiratory tract infection (RTI) and inflammation in patients with chronic obstructive lung diseases, such as cystic fibrosis (CF), periodically develops into exacerbations, where chronic colonization of the airway by bacteria causes severe decline in lung function, leading to increased hospitalization and high mortality rates (1, 2). Current antibiotic inhalation treatments approved for the management of chronic airway infections in cystic fibrosis are limited to tobramycin (TOBI®) and more recently, aztreonam (Cayston®). A major drawback to these localized treatments of RTIs is the rapid absorption and clearance of antibiotics from the lungs requiring multiple daily inhalations of high concentration antibiotic solutions. Hence, liposomal ciprofloxacin nanoparticles were developed to prolong lung residence time of the antibiotics, with the view to enhance antimicrobial activity and reduce the burden of therapy for the patients and their relatives who often have to assist them. Although in vivo studies with aerosolized delivery of liposomal ciprofloxacin have previously been performed on human and animal subjects, in vitro cell models may be better suited to study the transport, interactions of drugs and carrier systems, and drug localization within and on the airway cell epithelium at a molecular level. Therefore, the aim of this study was to investigate the newly developed system allowing nebulized liposomal ciprofloxacin to be delivered directly to the bronchial epithelial surface in an established air interface Calu-3 cell model.
Please use this identifier to cite or link to this item: